Nintedanib

Generic Name
Nintedanib
Brand Names
Ofev, Vargatef, Nintedanib Accord
Drug Type
Small Molecule
Chemical Formula
C31H33N5O4
CAS Number
656247-17-5
Unique Ingredient Identifier
G6HRD2P839
Background

Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only tw...

Indication

Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It is also indicated for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
...

Associated Conditions
Idiopathic Pulmonary Fibrosis (IPF), Respiratory Function Impaired, Chronic Progressive Fibrosing Interstitial Lung Disease, Locally advanced Non-Small Cell Lung Carcinoma (NSCLC), Locally recurrent Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
Associated Therapies
-
Clinical Trials
Related News

Nintedanib Treatment in Unicentric Castleman Disease

Phase 2
Not yet recruiting
Conditions
Castleman Disease
Interventions
Drug: Nintedanib
First Posted Date
2024-10-15
Last Posted Date
2024-10-15
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
13
Registration Number
NCT06643091

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

Phase 1
Not yet recruiting
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: GSK3915393
Drug: Nintedanib
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
38
Registration Number
NCT06625489

Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

First Posted Date
2024-08-26
Last Posted Date
2024-08-26
Lead Sponsor
Second Hospital of Shanxi Medical University
Target Recruit Count
40
Registration Number
NCT06570317
Locations
🇨🇳

Jinzhong third people's hospital, Jinzhong, Shanxi, China

🇨🇳

Jincheng General Hospital, Jincheng, Shanxi, China

🇨🇳

Frist Hospital of Shanxi Medical University, Taiyuan, Shanxi, China

and more 4 locations

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Participants
Interventions
Drug: Nintedanib
Drug: BMS 986278
First Posted Date
2024-08-23
Last Posted Date
2024-12-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
73
Registration Number
NCT06568458
Locations
🇺🇸

Local Institution - 0002, Lenexa, Kansas, United States

🇺🇸

ICON Lenexa, Lenexa, Kansas, United States

Real-life-persistence to Antifibrotic Treatments

Active, not recruiting
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Nintedanib
Drug: Pirfenidone
First Posted Date
2024-07-03
Last Posted Date
2024-11-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
800
Registration Number
NCT06485635
Locations
🇫🇷

Clinityx, Boulogne-Billancourt, France

RCT of Nintedanib in Fibrotic Sarcoidosis

Phase 4
Recruiting
Conditions
Sarcoidosis, Pulmonary
Interventions
Drug: Standard of care
Drug: Nintedanib
First Posted Date
2024-06-28
Last Posted Date
2024-10-23
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
120
Registration Number
NCT06479603
Locations
🇮🇳

Postgraduate Institute of Medical Education and Research, Chandigarh, India

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

First Posted Date
2024-03-06
Last Posted Date
2024-11-20
Lead Sponsor
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Target Recruit Count
86
Registration Number
NCT06297096
Locations
🇵🇱

Centrum Wsparcia Badań Klinicznych, Warsaw, Mazowieckie, Poland

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1015550
Drug: Nintedanib
Drug: Pirfenidone
First Posted Date
2023-10-06
Last Posted Date
2023-12-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT06070610
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Nintedanib
First Posted Date
2023-05-23
Last Posted Date
2024-09-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1798
Registration Number
NCT05870956
Locations
🇺🇸

Medicus Economics, LCC, Milton, Massachusetts, United States

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

First Posted Date
2023-04-18
Last Posted Date
2023-12-15
Lead Sponsor
Endeavor Biomedicines, Inc.
Target Recruit Count
21
Registration Number
NCT05817240
Locations
🇦🇺

Research Site, Adelaide, South Australia, Australia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy